logo
Hospital worker tears up as she recalls death of girl, 14, left alone on ward

Hospital worker tears up as she recalls death of girl, 14, left alone on ward

Yahooa day ago
A care worker at a children's mental health hospital broke down in tears during an inquest hearing as she recalled the moment she realised a suicidal teenage girl who should have been watched at all times had been left alone.
Ruth Szymankiewicz was being treated for an eating disorder at Huntercombe Hospital in Berkshire and had been placed under strict one-to-one observation when on February 12 2022, an inexperienced agency worker left her on her own.
The 14-year-old was able to shut herself in her bedroom at the hospital's psychiatric intensive care unit – also known as Thames ward – where she self-harmed.
She died two days later at John Radcliffe Hospital in Oxford.
It later emerged the member of staff responsible for watching Ms Szymankiewicz – a man then known as Ebo Acheampong – had never worked in a psychiatric hospital environment prior to coming to Huntercombe Hospital on February 12 for his first shift.
Michelle Hancey, a support worker with 18 years' experience at Huntercombe, teared up as she told a jury inquest on Wednesday about the moment Mr Acheampong told her he 'couldn't follow' Ms Szymankiewicz on the ward – and she realised the teenage girl was alone.
'He just said to me he couldn't follow his patient and when I asked him who his patient was, and when I found out it was Ruth, I told him he needed to look for her immediately,' Ms Hancey said.
Ms Szymankiewicz had been placed on the 'level three observation' plan following earlier incidents of self-harm – meaning she had to be kept within eyesight at all times on the ward.
Tim Moloney KC, who represents the family, told the hearing: 'What Ruth did on the 12th of February was not out of the blue.
'Those who worked on the ward knew that Ruth would take an opportunity (to self-harm) if it was presented to her.'
Mr Acheampong was asked to join the psychiatric intensive care unit on February 12 because the ward was so short-staffed nurses could not go on breaks, the inquest at Buckinghamshire Coroner's Court was previously told.
Ms Hancey further told jurors that, on the morning of February 12, she had become 'upset and emotional' because of the insufficient staffing on Thames ward.
'I have raised (staffing issues) several times before this event,' Ms Hancey said, adding a lot of staff had fallen sick during that period because of exhaustion.
'There was an agreement that I should have a certain amount of staff on the ward.
'We had very difficult patients and they kept going off.'
Ms Hancey filed a risk management form known as a 'Datix incident' on February 12 2022, in which she raised concerns that staff on Thames ward would 'fail to monitor patients on prescribed special observation because of staff shortage', Mr Moloney said.
The inquest previously heard Mr Acheampong never returned to work at the hospital following the incident and fled the UK for Ghana.
A police investigation later found he had been using false identity documents and was hired by the Platinum agency – which supplied staff for Huntercombe Hospital – under a false name.
Active Care Group, which owned Huntercombe at the time of Ms Szymankiewicz's death, has since closed the facility.
The inquest continues.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Could This Psychedelic Drug Stock Be a Top Buy for 2026?

Yahoo

time20 minutes ago

  • Yahoo

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Britain Forces Porn Sites to Get Serious on ‘Age-Gating'
Britain Forces Porn Sites to Get Serious on ‘Age-Gating'

New York Times

time2 hours ago

  • New York Times

Britain Forces Porn Sites to Get Serious on ‘Age-Gating'

Britain recently implemented new rules requiring internet users to verify their age before entering sites with content that is potentially harmful for children, including pornography and material encouraging violence or self-harm. The rules are part of the Online Safety Act, legislation passed in 2023 that is one of the most far-reaching efforts by a Western democracy to regulate online content. The new age-verification rules, which went into effect July 25, aim to shield minors from harmful online content, including from websites that promote suicide or eating disorders. The British government said that during the month of July alone, 16 percent of teenagers had seen material online that stigmatizes body types or promotes disordered eating. The rules are being closely watched in Europe, the United States and Australia, which plans in December to remove more than a million young teens from social media by setting a minimum age of 16. Here's what to know about the act: What do the rules cover? The act applies to websites, social media services, consumer file cloud storage and sharing sites, online forums, dating apps and instant messaging services. All are now required to verify visitors' ages if their platforms contain harmful or age-inappropriate content. Want all of The Times? Subscribe.

GMC: Burnout Drops, But Doctors Still Eyeing Exit
GMC: Burnout Drops, But Doctors Still Eyeing Exit

Medscape

time4 hours ago

  • Medscape

GMC: Burnout Drops, But Doctors Still Eyeing Exit

Doctors in the UK reported ' marginal, but clear' improvements in wellbeing in 2024, according to the General Medical Council (GMC). Its latest report found that overall satisfaction had risen, burnout risk had dropped, and workloads had eased slightly. However, almost one in five (19%) said they were considering leaving the UK to work abroad – a figure largely unchanged from 18% in 2022 and 20% in 2023. Career Stagnation a Major Concern A third of doctors said they were unable to progress in their education, training, or careers in the way they wanted. The GMC warned that heavy workloads, competition for posts, and lack of senior support for development were harming doctors' career prospects. The report found a clear link between career control and their overall wellbeing. Among doctors who felt able to progress as they wished, 81% reported job satisfaction and 59% were at very low risk of burnout. In contrast, only 33% of those lacking this sense of control were satisfied, and just 18% were at very low risk of burnout. GMC chief executive Charlie Massey said: 'Like any profession, doctors who are disillusioned with their careers will start looking elsewhere." Growing Interest in Overseas Work The report, based on responses from 4697 doctors around the UK, showed that 43% had looked into opportunities abroad. The top reason for considering emigration was the perception that doctors are 'treated better' overseas. Pay was the second most common reason. Some 15% had taken 'hard steps' towards leaving UK practice, such as applying for roles or contacting recruiters. 'We must be alive to the ongoing risks to retention of doctors and the impact of losing talented staff,' the report warned. 'This could threaten Government ambitions to reduce waiting times and deliver better care to patients.' GPs Under Greatest Strain The findings highlighted notable differences between specialties, with general practitioners facing particularly high levels of pressure. GPs were 50% more likely to be struggling compared with all doctors (44% versus 29%). Nearly half (46%) said they were dissatisfied, compared with 33% of all doctors. In addition, 61% of GPs said they found it difficult to provide adequate patient care at least once a week, compared with 40% of all doctors. Burnout Down, Stress Leave Up The proportion of doctors at high risk of burnout dropped from 25% in 2022 to 18% in 2024. However, almost a quarter (23%) took a leave of absence due to stress in 2024 – nearly double the 12% reported in 2019. Although 59% of doctors were satisfied with their day-to-day work in 2024 — up from 53% in 2023 — this remained lower than the 2019 figure of 63%. 'Without action, ambitions to move more patient care from hospitals to communities may well be thwarted,' the GMC warned. Patient Safety Still at Risk In 2024, 40% of doctors said they had seen patient safety being compromised – a figure broadly in line with previous years. The same proportion reported struggling to provide sufficient care weekly – slightly down from 43% in 2023 but still higher than the 34% in the pre-pandemic year of 2019. Inadequate staffing remained the most frequently reported barrier to care, cited by 72% of doctors. Regional Variations Doctors in England, Scotland, and Wales generally reported workplace experiences in line with the UK average. However, in Northern Ireland, responses were notably more negative. There, 26% of doctors were at high risk of burnout compared with an 18% UK average. More than half (54%) said they struggled to provide patient care at least once a week, compared with an average of 40% across the UK as a whole. 'Doctors need to be satisfied, supported, and see a hopeful future for themselves, or we may risk losing their talent and expertise altogether,' warned Massey. Reaction to the Report Commenting on the GMC report, Billy Palmer, senior fellow at the Nuffield Trust think tank, said: 'Pay and industrial action have been a lightning rod for dissatisfaction among doctors, but this survey puts a spotlight on the wider difficulties facing the medical profession. Job guarantees, better rotas and placements, and protection of training time all need to be on the table.' Daniel Elkeles, chief executive of NHS Providers, called for the report's findings to be taken seriously by the NHS. 'It is encouraging to see 'green shoots' emerging, including improvements in doctors' workplace experiences for the second year in a row, and a reduction in burnout risk,' he said. 'But more needs to be done to get back to where we were before the pandemic.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store